Celal KARLIKAYA, Çakır Ebru EDİS

The cost of lung cancer in Turkey

AMAÇ: Bu çalışmada Türkiye’de akciğer kanserinin hastalara ve topluma yüklediği bedelleri ortaya çıkarmayı amaçladık.Hastalar: Ocak 2002-Şubat 2003 tarihleri arasında Göğüs Hastalıkları Kliniği'ne başvuran 103 akciğer kanseri olgusu prospektif olarak çalışmaya alındı.YÖNTEM: Primer sonlanım ölçütü çalışmanın sonuna veya hastalar ölene kadar hastalıklarının maliyetini ölçmekti. Tüm maliyetler tespit edildiği günkü efektif satış kuru üzerinden dolara çevrilerek kaydedildi. Verilerin değerlendirilmesinde tanımlayıcı istatistikler, ki-kare, Fisher testi, Kaplan- Meier Analizi ve non-parametrik “Bootstraping” yöntemleri kullanıldı.SONUÇLAR: Ortalama sağ kalım süresi 6.8 aydı. Direk tıbbi maliyet toplam 564,960 ABD Doları iken hasta başına ortalama direk maliyet 5,480±4,088 dolar idi. Akciğer kanseri toplam maliyeti çalışma grubunda 1,473,530 dolar ve hasta başına ortalama 14,306±17,705 dolar idi. Her bir yaşam yılının direk tıbbi maliyeti ortalama 18,058± 25,775 $ olarak hesaplandı. Cinsiyet, yaş ve histopatolojinin etkisi yok iken hastalık evresi arttıkça direk tıbbi maliyet de artmaktaydı.TARTIŞMA: Düşük yaşam beklentisi ve kür oranları da düşünüldüğünde, akciğer kanseri ülkemizde özelikle maliyet azaltıcı ve tütünün kontrolüne yönelik önlemlerin önemine işaret etmektedir.

Türkiye'de akciğer kanserinin maliyeti

OBJECTIVES: The aim of this study was to evaluate the individual and societal burden of lung cancer in Turkey.Patients: A total of 103 cases with lung cancer attended our department between January 2002 and February 2003 were included in our study prospectively.Design: The primary outcome measure was the cost of disease until death of the patients or the end of study. All the costs were expressed as US dollars and were estimated regarding the effective exchange rate at the time of recording. Descriptive statistics, chi-square, Fisher’s exact test, Kaplan-Meier analysis and non-parametric “Bootsraping” tests were performed to evaluate the data. RESULTS: The average survival was 6.8 months. The estimated total direct cost for the entire group was 564,490 USD, and the direct cost per patient was 5,480 ± 4,088 USD. The total cost of lung cancer in the study group was 1,473,530 USD, with a per-patient cost of 14,306 ± 17,705 USD. The average direct cost per life year was 18,058 ± 25,775 USD. Age, gender and histopathology did not affect the cost, whereas direct medical costs were increased with increasing stage.CONCLUSIONS: With the low life expectancy and cure rates, lung cancer has been alerting for the cost minimization and disease control measures.

PDF

___

1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 35.
2. Fidaner C, Eser SY, Parkin DM. Incidence in Izmir in 1993-1994: First results from İzmir Cancer Registry. Eur J Cancer 2001; 37: 83-92.0: 379-92.
3. Goksel T, Akkoclu A. Turkish Thoracic Society, Lung and Pleural Malignancies Study Group. Pattern of lung cancer in Turkey, 1994-1998. Respiration 2002; 69: 207-10.
4. Vergnenegre A, Molinier L, Chouaid C. Economic analysis and lung cancer. Monaldi Arch Chest Dis 2001; 56: 334-41.
5. Central Bank Daily Exchange Rates. http://www.tcmb. gov.tr
6. Barber JA, Thompson SG. Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Stat Med 2000; 19: 3219-36
7. Evans WK, Will BP, Berthelot JM, et al. The economics of lung cancer management in Canada. Lung Cancer 1996; 14: 19-29.
8. Evans WK, Will BP, Bertholot JM, et al. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. Br J Cancer 1995; 72: 1270-7.
9. Esin A, Bilir N, Aslan D. Health care expenditures of lung cancer: A Turkish Experience. Turkish Respiratory Journal 2004; 5: 159-63.
10. Lees M, Aristides M, Maniadakis N, et al. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325-37.
11. Ernam D, Atalay F, Atikcan Ş. A retrospective evaluation of 571 lung carcinoma patients. Turkish Respiratory Journal 2003; 4: 67-9.
12. Rosenthal MA, Webster PJ, Gebski VJ, et al. The cost of treating small cell lung cancer. Med J Aust 1992; 156: 605-10.
13. Oliver E, Kilen J, Kiebert G, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001; 56: 785-90.
14. Wolstenholme JL, Whynes DK. The hospital costs of treating lung cancer in the United Kingdom. Br J Cancer 1999; 80: 215-8.
15. Yurdakul AS, Çalışır HC, Demirağ F, et al. Distribution of lung cancer by histological types. Toraks Dergisi 2002; 3: 59-65 [In Turkish with English Abstract].
16. Çilli A, Özdemir T, Özbulak Ö, et al. Coincidence of COPD in lung cancer patients. Solunum 2003; 5: 20-4 [In Turkish with English Abstract].
17. Broome CM, Borum M. Women’s health issues. Med Clin North Am 1998; 82: 321-33.
18. Karlikaya C, Cakir Edis E. Lung cancer histopathology in the Thrace region of Turkey and comparasion with national data. Tuberk Toraks 2005; 53: 132-8.
19. Bordeleau L, Goodwin PJ. Economic issues in lung cancer. Semin Respir Crit Care Med 2000; 21: 375-83.
20. Beltz SE, Yee GC. Pharmacoeconomics of cancer therapy. Cancer Control JMCC 1998; 5: 415-24.